Long-Term Growth Hormone Therapy Changes the Natural History of Body Composition and Motor Function in Children with Prader-Willi Syndrome
Open Access
- 1 March 2010
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (3), 1131-1136
- https://doi.org/10.1210/jc.2009-1389
Abstract
Background: Children with Prader-Willi syndrome (PWS) have decreased muscle mass, hypotonia, and impaired linear growth. Recombinant human GH (hGH) treatment reportedly improves body composition and physical function in children with PWS, but these studies lack long-term control data. To assess the impact of hGH therapy begun early in life on the natural history of PWS, we compared height, body composition, and strength in similar-age children with PWS naïve to hGH with those treated with hGH for 6 yr. Objectives: Forty-eight children with PWS were studied: 21 subjects (aged 6–9 yr) treated with hGH for 6 yr (beginning at 4–32 months, mean 13 ± 6 months) were compared with 27 children of similar age (5–9 yr) prior to treatment with hGH. Percent body fat, lean body mass, carbohydrate/lipid metabolism, and motor strength were compared using analysis of covariance. Results: PWS children treated with hGH demonstrated lower body fat (mean, 36.1 ± 2.1 vs. 44.6 ± 1.8%, P < 0.01), greater height (131 ± 2 vs. 114 ± 2 cm; P < 0.001), greater motor strength [increased standing broad jump 22.9 ± 2.1 vs. 14.6 ± 1.9 in. (P < 0.001) and sit-ups 12.4 ± 0.9 vs. 7.1 ± 0.7 in 30 sec (P < 0.001)], increased high-density lipoprotein cholesterol (58.9 ± 2.6 vs. 44.9 ± 2.3 mg/dl, P < 0.001), decreased low-density lipoprotein (100 ± 8 vs. 131 ± 7 mg/dl, P < 0.01), and no difference in fasting glucose or insulin. Conclusions: hGH treatment in children with PWS, begun prior to 2 yr of age, improves body composition, motor function, height, and lipid profiles. The magnitude of these effects suggests that long-term hGH therapy favorably alters the natural history of PWS to an extent that exceeds risks and justifies consideration for initiation during infancy.Keywords
This publication has 24 references indexed in Scilit:
- Retrospective Study of the Potential Benefits and Adverse Events during Growth Hormone Treatment in Children with Prader-Willi SyndromeThe Journal of Pediatrics, 2009
- Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader–Willi syndromeClinical Endocrinology, 2008
- Growth Hormone Treatment Completely Normalizes Adult Height and Improves Body Composition in Prader-Willi Syndrome: Experience from KIGS (Pfizer International Growth Database)Hormone Research in Paediatrics, 2008
- Sudden Death in Prader-Willi Syndrome: Brief Review of Five Additional CasesHormone Research in Paediatrics, 2006
- Deaths in Children with Prader-Willi SyndromeHormone Research in Paediatrics, 2005
- Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndromeThe Journal of Pediatrics, 2004
- Growth hormone and body composition in children younger than 2 years with Prader-Willi syndromeThe Journal of Pediatrics, 2004
- Decreased energy expenditure is caused by abnormal body composition in infants with Prader-Willi SyndromeThe Journal of Pediatrics, 2003
- Growth Hormone Treatment of Children with Prader-Willi Syndrome: Effects on Glucose and Insulin HomeostasisHormone Research in Paediatrics, 1999
- Growth Hormone Secretion in Prader‐Willi SyndromeActa Paediatrica, 1990